THERAVET
25.10
EUR
(-0.16%)
03/27/2025 - 19:59
Closed 15 min delayed data - Euronext Paris
| Open: | 25.06 |
| Change: | -0.04 |
| Volume: | 11,593 |
| Low: | 25.02 |
| High: | 25.25 |
| High / Low range: | 0.23 |
| Type: | Stocks |
| Ticker: | ALVET |
| ISIN: | BE0974387194 |
THERAVET news, videos and press releases
For more news please use our advanced search feature.
THERAVET - More news...
THERAVET - More news...
- 01/28/2025 - 15:00 Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover
- 11/18/2024 - 17:00 EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance
- 07/11/2023 - 05:30 TheraVet provides an update on its 2023 half-year development and portfolio strategy
- 06/15/2023 - 05:30 TheraVet Announces 300% Increase in Participating Centers in the Osteosarcoma Program Since Its Initiation 6 Months Ago
- 05/31/2023 - 05:30 TheraVet Announces the Commercial Launch of a Local and Sustained Antibiotic Releasing Bone Substitute
- 05/04/2023 - 05:30 TheraVet Continues the Assessment of BIOCERA-VET in a New Clinical Program
- 04/25/2023 - 05:30 TheraVet reports Full-Year 2022 Financial Results and provides the preparatory documents for the General Assembly of June 1st, 2023
- 04/06/2023 - 05:30 TheraVet Launches its Osteosarcoma Reference Centers Program
- 03/28/2023 - 05:30 TheraVet Updates on Its Development and Portfolio Strategy
- 02/21/2023 - 06:30 TheraVet Signs an International Distribution Agreement for BIOCERA-VET® Covering 24 Countries
- 02/15/2023 - 16:45 TheraVet Announces the Start of the Assessment of BIOCERA-VET® in Horse Bone Cyst
- 12/12/2022 - 06:30 TheraVet Optimizes Its Commercial Strategy in France With a New Distribution Agreement for Its BIOCERA-VET® Range
- 12/07/2022 - 06:30 TheraVet: BIOCERA-VET® Nominated for the Veterinary Innovation Award (AFVAC 2022)
- 09/26/2022 - 05:30 TheraVet Announces an Exclusive Distribution Agreement for BIOCERA-VET® in the USA
- 09/19/2022 - 05:30 TheraVet Announces Its Participation in the 2022 ESVOT Congress With 3 Scientific Communications
- 09/09/2022 - 05:30 TheraVet Reports Its 2022 Half-year Results and Provides an Update on the Development of Its Activities
- 06/30/2022 - 15:45 TheraVet Provides Its 2022 First Half-year Operational Update
- 06/30/2022 - 05:30 TheraVet Annonces the Commercial Launch of its BIOCERA-VET Product Line in the United States of America
- 06/02/2022 - 05:30 TheraVet Annonces the Commercial Launch of the Most Comprehensive Line of Bone Substitutes in the Veterinary Market
- 05/30/2022 - 05:30 TheraVet Signs a Distribution Agreement With Nuzoa, a Leading Spanish Company in the Distribution of Veterinary Products and Services
- 05/12/2022 - 05:30 TheraVet: General Meeting of June 2, 2022: Availability of Preparatory Documents
- 05/10/2022 - 05:30 TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation
- 04/06/2022 - 05:30 TheraVet Reports Full Year 2021 Financial Results and Confirms Its Ambitious Development and Commercial Plans for 2022
- 03/28/2022 - 05:30 TheraVet: Market-making Agreement with Banque Rothschild
- 03/15/2022 - 06:30 TheraVet: Commercial Launch of BIOCERA-VET® in United Kingdom and Ireland
- 02/07/2022 - 06:30 TheraVet Broadens Its Bone Substitutes Portfolio With an Innovative Line of Biological Bone Grafts
- 02/04/2022 - 06:30 TheraVet: Positive Results of BIOCERA-VET®-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort
- 01/25/2022 - 06:30 TheraVet Provides Its 2021 Second Half Operational Update
- 01/18/2022 - 06:30 TheraVet Strengthens Its Sales Organisation in France by Signing an Important Distribution Agreement for BIOCERA-VET®
- 01/10/2022 - 16:58 TheraVet Announces the Initiation of Coverage of Its Stock by Degroof Petercam
